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negative impact on growth course and bone age advance-
ment nor on BMI in LE group.
Conclusion Prepubertal LE is associated with healthier 
lipid profile than CE in girls with TS.
Keywords Turner syndrome · Estrogen · Lipid profile · 
Glucose
Introduction
The estrogens are a group of steroid sex hormones that are 
essential for normal female development. Although their 
most important physiological role in girls is development 
of secondary sexual characteristics during puberty, it has 
been shown that they are secreted by ovaries already in the 
prepubertal period. The meaning of that phenomenon in 
healthy girls remains unclear; however, there are some evi-
dence for their contribution in physical and psychological 
development [1–3]. It is suggested that prolonged estrogen 
deficiency in girls with hypogonadism that begins in early 
childhood or even in infancy may have negative effects 
across many body systems [4]. One of the most common 
causes of female hypogonadism is Turner syndrome (TS) 
that occurs in approximately 1/2000 live female births [5]. 
It results from complete or partial X chromosome mono-
somy, which in approximately 90% of affected girls causes 
ovarian dysgenesis and subsequent estrogen deficiency 
that begins in early infancy [6, 7]. Patients with TS present 
short stature treatable with growth hormone that makes it 
possible to reach final height >(−)2.0 SDS in about 62% 
[8]. Additionally, patients with TS are at risk of metabolic 
disorders such as glucose intolerance or dyslipidemia [6]. 
Despite estrogen replacement is a treatment of choice for 
pubertal induction in adolescent girls with TS since 1960s, 
Abstract 
Purpose The metabolic effects of prepubertal low-dose 
estrogen replacement (LE) therapy in Turner syndrome 
(TS) have not been fully investigated to date. The present 
study aimed to compare glucose and lipids metabolism 
in adolescents with TS on LE and conventional estrogen 
replacement (CE).
Methods In 14 TS (mean age 13.8), LE (17β-estradiol, 
62.5  μg daily) was introduced before age 12 (mean age 
10.5), and followed by a pubertal induction regimen after 
age 12, and in 14 CE was started after age 12 (mean 14, 
SD 1.96). Before, and 3  years after starting 17β-estradiol 
growth velocity, bone age, BMI, and selected parameters of 
glucose and lipids metabolism were assessed.
Results There were no significant differences between LE 
and CE in the mean levels of any parameter before intro-
duction of 17β-estradiol [total cholesterol (TC): 4.1 vs 
4.3 mmol/L, LDL cholesterol (LDLc): 2.2 vs 2.4 mmol/L, 
HDL cholesterol (HDLc): 1.6 vs 1.4 mmol/L, triglycerides: 
0.9 vs 1.0  mmol/L, fasting glucose: 4.2 vs 4.4  mmol/L, 
post-load glucose: 4.8 vs 5.5 mmol/L; fasting insulin: 6.8 
vs 8.0 post-load insulin: 21.3 vs 67.0  μIU/mL, HOMA-
IR 1.3 vs 1.6]. After three years of treatment, TC and 
LDLc levels were significantly lower in LE group (3.8 vs 
4.4 mmol/L, p = 0.004; 1.9 vs 2.4 mmol/L, p = 0.03). The 
other parameters did not differ significantly. There was no 
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many concerns relate to the potential benefits of the ini-
tiation of such treatment in younger patients [4, 9]. The 
studies concerning metabolic effect of the early estrogen 
replacement are lacking. However, recently published data 
show that prepubertal low-dose estrogen replacement is 
more physiologic, and can optimize response to growth 
hormone treatment, pubertal timing, and improve cognition 
[4, 10]. Moreover, only early estrogen replacement therapy 
can prevent osteoporosis and provide proper psychosocial 
development through slower, more physiological process of 
puberty [11–16]. Nevertheless, early exposure to the exces-
sive concentrations of sex hormones may have negative 
impact on growth and pubertal development as well. To 
date, there are no guidelines supporting the optimal choice 
of an age of initiation, dosage, or route of administration 
of estrogen replacement in prepubertal girls with TS. The 
results of our present study may provide novel insights into 
metabolic consequences of early estrogen deficiency and its 
replacement in prepubertal patients with TS.
Materials and methods
The study conducted in the Department of Pediatric 
and Adolescent Endocrinology in Children’s University 
Hospital in Krakow included 28 TS patients [16 with 
X chromosome monosomy (45,X), 5 with abnormal X 
chromosome—[three with 46, Xi(Xq), one with 46,XX 
del (Xq)], and one with 45,X t(3;8)(p23;p11)] and 7 
with mosaicism [three with 45,X/46,Xi(Xq) 50/50%, 
one with 45,X/46,XX 90/10%; 1 with 45,X/46,Xi(Xq) 
70/30% one with 45,X/46,X derX 65/35%, and one with 
46,XY[27]/45,X[18] 60/40%] treated with human recom-
binant growth hormone. Before entering the study, in all 
participants, hypergonadotropic hypogonadism due to 
ovarian failure was confirmed on the basis of elevated 
follitropin levels. In the Low Estrogen (LE) Dosage 
Group (n = 14, mean age 13.8, SD 1.55), low dose of oral 
17β-estradiol [62.5  μg once daily; Estrofem mite (Novo 
Nordisk) pills containing 1  mg of 17β-estradiol were 
splitted by pharmacist] was introduced before the age of 
12 (mean 10.5, SD 0.95), and was followed by a stand-
ard pubertal induction regimen after the age of 12. In the 
Conventional Estrogen (CE) Dosage Group (n = 14, mean 
age 16.4, SD 1.64), pubertal induction (Estrofem mite 
(Novo Nordisk) pills containing 1  mg of 17β-estradiol) 
was started in accordance with present standards, after 
the age of 12 (mean 14, SD 1.96).
In all participants before and 3  years after starting 
17β-estradiol, total cholesterol (TC), LDL cholesterol 
(LDLc), HDL cholesterol (HDLc), and triglycerides (TG) 
were measured in the fasting blood sample by the dry 
chemistry method with a Vitros 5.1.FF machine (Ortho 
Clinical Diagnostics, Rochester, NY, USA). LDL choles-
terol was measured indirectly.
Standard oral glucose tolerance test was performed 
with the assessment of fasting (G0) and after 120′ post-
load of glucose (G120) and insulin levels (I0, I120). Insu-
lin resistance index (HOMA-IR) was calculated. We also 
analyzed the course of growth, BMI changes, and bone 
age advancement during the study period in both groups. 
The estradiol levels in the blood have not been investi-
gated during the study.
To compare the two sets of data, the T student or two-
sided Mann–Whitney U test was used. The level of signif-
icance was set at p < 0.05. Calculations were performed 
using the STATISTICA 12.0 PL software.
Table 1  Comparison of the auxological data in LE and CE groups at the beginning, 1 and 3 years after of different models of 17beta estradiol 
regimen dosage—low dose in prepubertal and conventional dose in pubertal period
Statistically significant results are bolded
17βE introduction 1 year after 17βE introduction 3 years after 17βE introduction
Mean [SD] p Mean [SD] p Mean [SD] p
LE CE LE CE LE CE
Age [years] 10.6 [0.9] 14 [2.0] <0.0001
Body height [cm] 129.37 [6.8] 139.3 [9.7] 0.012 136.3 [6.5] 144.6 [1.4] 0.005 146.8 [9.8] 152.2 [7.2] 0.22
Body height [SDS] −2.2 [0.9] −3.2 [1.4] 0.045 −2.11 [0.9] −2.89 [1.0] 0.06 −2.1 [1.1] −2.04 [1.2] 0.9
Body mass index [kg/m2] 17.0 [2.1] 19.3 [5.1] 0.30 18.27 [2.7] 20.23 [5.7] 0.45 20.0 [3.5] 21.8 [5.6] 0.45
Body mass index [SDS] −0.2 [0.7] −0.03 [1.5] 0.87 0.07 [0.9] 0.1 [2.0] 0.53 0.18 [1.3] 0.45 [2.1] 0.90
Bone age [years] 10.1 [1.5] 12.1 [1.3] 0.002 11.5 [1.2] 13.3 [0.8] 0.0004 13.2 [1.7] 14.6 [0.9] 0.8
Age of breast development (ThII) 11.0 [0.6] 13.6 [1.0] <0.0001
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Results
Despite exposure to estrogens in prepubertal age, we 
observed no negative impact on growth course and bone 
age advancement nor on BMI in LE group (Table  1). 
There was no case of premature breast development in 
LE group. At the moment of 17β-estradiol introduction, 
the mean height SDS were significantly lower in LE in 
comparison to CE (−2.2 vs −3.2, p = 0.045). One and 
3  years after low-dose 17β-estradiol introduction, we 
revealed no significant impact on growth velocity, con-
trary to patients receiving standard doses of 17β-estradiol 
at the age of puberty that presented increase of growth 
velocity. After 1  year of 17β-estradiol replacement, 
the advance of the bone age was 1.4  years in LE and 
2.4  years in CE; the difference was not statistically sig-
nificant. After 3  years, the advancement in both groups 
(LE and CE) was 3.07 and 3.1 years, respectively; the dif-
ference was also not statistically significant. There were 
no significant differences between LE and CE in any 
assessed parameters before introduction of 17β-estradiol 
(TC 4.1 vs 4.3 mmol/L, LDLc 2.2 vs 2.4 mmol/L, HDLc 
1.6 vs 1.4  mmol/L, TG 0.9 vs 1.0  mmol/L, G0 4.2 vs 
4.4 mmol/L, G120 4.8 vs 5.5 mmol/L; I0 6.8 vs 8.0 µIU/
mL, I120 21.3 vs 67.0  μIU/mL; HOMA-IR 1.3 vs 1.6). 
Three years after 17β-estradiol, TC and LDLc levels 
were significantly lower in LE group (3.8 vs 4.4 mmol/L, 
p = 0.004; 1.9 vs 2.4  mmol/L, p = 0.03). The other 
parameters did not differ significantly (HDLc 1.5 vs 
1.6 mmol/L TG 1.2 vs 1.3 mmol/L G0 4.6 vs 4.8 mmol/L 
G120 5.2 vs 6.0 mmol/L; I0 12.3 vs 15.6 µIU/mL, I120 
62.7 vs 83.7 μIU/mL; HOMA-IR 2.5 vs 3.6), for details, 
see Table 2.
Discussion
Ovarian dysgenesis is considered as the most important 
consequence of X chromosome monosomy. The first overt 
manifestation of the hypogonadism in patients with TS is 
lack or delay of secondary sexual characteristics develop-
ment. Nevertheless, estrogen deficiency begins earlier, in 
early childhood or even in infancy and probably, has many 
consequences for the general development and well-being. 
Therefore, there were few attempts of the assessment of 
the possible effect of the early, before the age of puberty 
induction of estrogen replacement therapy. Charmian et al. 
previously demonstrated that individual regimen of low-
dose estrogen replacement from the age of 5 caused slower, 
more physiological tempo of puberty and did not influence 
the bone age progression, time of menarche, and age of 
developing breast stages Th > II [4]. Some reports demon-
strated the importance of early estrogen replacement for 
psychosocial development and self-esteem, and better cog-
nitive abilities, e.g., memory, processing speed, and motor 
performance [15–18]. However, this type of replacement 
treatment remains an experimental method to date. One of 
the arguments for the delay of estrogen replacement therapy 
till the age of puberty is concern about the possible nega-
tive impact of early estrogen exposure on skeletal matura-
tion and final growth. That has been denied by Ross et al. in 
a study that proved favorable impact of prepubertal estro-
gen replacement combined with growth hormone for the 
optimization of height gain [10]. Also in our study, we did 
not observe any negative consequences of prepubertal low-
dose estrogen replacement therapy on the growth course. 
The analysis of the skeletal maturation also showed no del-
eterious effects of early estrogen introduction. After 1 year 
Table 2  Comparison of the 
selected parameters of glucose 
and lipids metabolism in LE 
and CE groups at the beginning, 
and 3 years after of different 
models of 17beta estradiol 
regimen dosage—low dose in 
prepubertal and conventional 
dose in pubertal period
Statistically significant results are bolded
Undesirable level (>95th percentile) of lipid fractions in children TC ≥5.17 mmol/L, LDLc ≥3.36 mmol/L, 
TG ≥1.47 mmol/L, HDL c <0.91 mmol/L [14]
TC [mmol/L] 17βE introduction 3 years after 17βE introduction
Mean [SD] p Mean [SD] p
LE CE LE CE
4.1 [0.7] 4.3 [0.6] 0.4 3.8 [0.4] 4.4 [0.5] 0.004
LDLc [mmol/L] 2.2 [0.8] 2.4 [0.7] 0.6 1.9 [0.4] 2.4 [0.5] 0.03
HDLc [mmol/L] 1.6 [0.3] 1.4 [0.3] 0.1 1.5 [0.3] 1.6 [0.5] 0.6
TG [mmol/L] 0.9 [0.4] 1.0 [0.4] 0.4 1.2 [0.5] 1.3 [0.5] 0.8
LDLc/HDLc 1.5 [0.65] 1.8 [0.66] 0.3 1.4 [0.6] 1.7 [1.7] 0.3
G0 [mmol/L] 4.2 [0.5] 4.4 [0.4] 0.2 4.6 [0.4] 4.8 [0.6] 0.3
G120 [mmol/L] 4.8 [1.0] 5.5 [1.2] 0.1 5.2 [1.7] 6.0 [1.7] 0.2
I0 [µIU/mL] 6.8 [1.7] 8.0 [3.0] 0.3 12.3 [5.2] 15.6 [8.5] 0.2
I120 [µIU/mL] 21.3 [15.5] 67.0 [37.2] 0.1 62.7 [52.8] 83.7 [58.8] 0.4
HOMA-IR 1.3 [0.4] 1.6 [0.7] 0.2 2.5 [1.1] 3.6 [2.1] 0.1
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of 17β-estradiol replacement, the advance of the bone age 
in LE group was 1.4 year, less than in CE group (2.4). After 
3 years, the advancement in both groups (LE and CE) was 
comparable: 3.07 and 3.1 years, respectively. Another open 
question is a role of prepubertal estrogen replacement ther-
apy in prevention of the development of metabolic disor-
ders. This has not been investigated to date. Development 
of the metabolic disorders is a serious problem in patients 
with TS as they have a fourfold increased relative risk of 
the insulin resistance, diabetes mellitus, and subsequent 
complications, which contribute up to 25% of the causes 
of death in adult TS patients [19]. Elevated TC and LDLC 
concentrations in childhood, and especially adolescence, 
are considered as predicted factors of atherosclerosis in the 
future [20]. The causes of metabolic disorders in patients 
with TS tend to be much more complex than in general 
population. Because of short stature and abnormal body 
proportions, women with Turner syndrome are more likely 
to be overweight and obese. However, metabolic disorders 
such as impaired insulin sensitivity, hypercholesterolemia, 
and liver steatosis are often diagnosed even in non-obese 
ones [21, 22]. Some data point that metabolic disturbances 
may be associated with the origin of the X chromosome 
monosomy itself. Moreover, patients who retained their 
maternal X present with higher BMI and lower total and 
low-density lipoprotein cholesterol [21]. Also insulin resist-
ance is thought to be connected not only with body weight 
and composition but also with the karyotype [23]. As it was 
recently shown in survey, overall metabolic risk in normal-
weight women with Turner syndrome is lower than in obese 
peers and some other mechanisms, e.g., FGF 21 may play 
an important role in this phenomenon [22]. The influence 
of growth hormone treatment and estrogen replacement 
on metabolism of patients with TS is significant. Growth 
hormone through its anabolic activity can improve body 
proportions, but on the other hand can also increase insu-
lin resistance [21]. However, increase of the insulin growth 
factor-1 (IGF-1) level, especially within the first months of 
treatment, may temporary improve insulin sensitivity, even 
in patients with pre-existing insulin resistance. The impact 
of estrogen replacement in TS patients on glucose metabo-
lism seems to be more complex and remains unclear. Some 
authors have shown that estrogen replacement promotes 
obesity, insulin resistance, and hypercholesterolemia [24]. 
On the other hand, there are studies negating the relation-
ship between exogenous estrogens and insulin resistance 
and glucose metabolism disorders [23]. Additionally, 
recently published metaanalysis of the studies performed in 
menopausal women has shown that low estrogen replace-
ment has favorable effect on lipid profile in that group of 
patients [25]. In the present study, we decided to investi-
gate whether low dose (62.5 μg daily) of oral 17β-estradiol 
replacement would impact the metabolic status of patients 
with TS. Our results clearly show a beneficial effect of such 
treatment for lipid profile. There were no significant dif-
ferences between LE and CE in any assessed parameters 
of glucose and lipids metabolism before introduction of 
17β-estradiol. After three years, mean TC and LDLc lev-
els were still within normal ranges in both groups, how-
ever, significantly lower in LE group (3.8 vs 4.4 mmol/L, 
p = 0.004; 1.9 vs 2.4 mmol/L, p = 0.03). The main limita-
tions of the present study are relatively small group of 
participants and lack of serum estradiol levels measure-
ments during replacement therapy. The another issue, that 
may raise doubts is the real impact of such a small dose 
of 17β-estradiol for improving the lipid profile. Since the 
administration of 62.5 ug of 17β-estradiol caused no visible 
effect on the traditionally considered “estrogen-dependent” 
tissues as for, e.g., breast tissue or growth cartilage, could it 
improve the lipid profile? To confirm this observation, fur-
ther investigation in larger groups of TS patients is needed. 
Nevertheless, results of the studies that compared low 
doses of estrogens vs placebo in postmenopausal women 
show that low-dose estrogen replacement therapy was asso-
ciated with healthier lipid profile [25]. Despite these limita-
tions, results of the study provide next argument supporting 
consideration of early estrogen therapy showing no nega-
tive impact on growth and skeletal maturation and positive 
metabolic effects. Further investigations in this field are 
needed for better understanding of the role of estrogens in 
the prepubertal period and development of better standards 
of comprehensive care for patients with Turner syndrome.
Conclusion
Prepubertal LE is associated with healthier lipid profile 
than CE in girls with TS. LE should be considered for 
girls with TS not only due to positive effects on growth 
and puberty course but also because of its positive meta-
bolic effects.
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